240 related articles for article (PubMed ID: 24762461)
1. Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice.
Toth PP; Shah PK; Wilkinson MJ; Davidson MH; McCullough PA
Rev Cardiovasc Med; 2014; 15(1):1-10. PubMed ID: 24762461
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.
Vuorio A; Tikkanen MJ; Kovanen PT
Vasc Health Risk Manag; 2014; 10():263-70. PubMed ID: 24851052
[TBL] [Abstract][Full Text] [Related]
3. Lomitapide for the management of homozygous familial hypercholesterolemia.
deGoma EM
Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128
[TBL] [Abstract][Full Text] [Related]
4. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
Gouni-Berthold I; Berthold HK
Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
[TBL] [Abstract][Full Text] [Related]
5. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia.
Stefanutti C
Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261
[TBL] [Abstract][Full Text] [Related]
6. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
[TBL] [Abstract][Full Text] [Related]
7. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.
Won JI; Zhang J; Tecson KM; McCullough PA
Rev Cardiovasc Med; 2017; 18(1):21-28. PubMed ID: 28509890
[TBL] [Abstract][Full Text] [Related]
8. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
[TBL] [Abstract][Full Text] [Related]
9. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
Rader DJ; Kastelein JJ
Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
[No Abstract] [Full Text] [Related]
10. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia.
Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D
Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578
[TBL] [Abstract][Full Text] [Related]
11. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia.
Davis KA; Miyares MA
Am J Health Syst Pharm; 2014 Jun; 71(12):1001-8. PubMed ID: 24865757
[TBL] [Abstract][Full Text] [Related]
12. Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia.
Sirtori CR; Pavanello C; Bertolini S
Ann Med; 2014 Nov; 46(7):464-74. PubMed ID: 24987866
[TBL] [Abstract][Full Text] [Related]
13. Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort.
Averna M; Cefalù AB; Stefanutti C; Di Giacomo S; Sirtori CR; Vigna G
Nutr Metab Cardiovasc Dis; 2016 Jan; 26(1):36-44. PubMed ID: 26723464
[TBL] [Abstract][Full Text] [Related]
14. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
[TBL] [Abstract][Full Text] [Related]
15. Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting.
Mahzari M; Zarif H
Adv Ther; 2021 May; 38(5):2159-2169. PubMed ID: 33829367
[TBL] [Abstract][Full Text] [Related]
16. ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report.
Reeskamp LF; Millar JS; Wu L; Jansen H; van Harskamp D; Schierbeek H; Gipe DA; Rader DJ; Dallinga-Thie GM; Hovingh GK; Cuchel M
Arterioscler Thromb Vasc Biol; 2021 May; 41(5):1753-1759. PubMed ID: 33691480
[TBL] [Abstract][Full Text] [Related]
17. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide.
Roeters van Lennep J; Averna M; Alonso R
J Clin Lipidol; 2015; 9(4):607-17. PubMed ID: 26228681
[TBL] [Abstract][Full Text] [Related]
18. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia.
Perry CM
Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.
Cuchel M; Blom DJ; Averna MR
Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075
[TBL] [Abstract][Full Text] [Related]
20. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.
Ito MK; Watts GF
Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
